STAT Plus: 7 things to know about Aimmune’s peanut allergy therapy ahead of a pivotal FDA meeting

The Food and Drug Administration is bringing together a panel of outside experts to review a novel but controversial treatment that aims to protect people against severe peanut allergy.

The convening of the FDA advisory panel, scheduled to meet — and vote — on Sept. 13, will be a pivotal moment for Aimmune Therapeutics, the biopharma company that developed the new treatment, called AR101. If approved, AR101 will be the first protective therapy for peanut allergy and the start of what Aimmune hopes will be a family of products with blockbuster commercial potential — all designed to benefit the millions of people who suffer with life-threatening food allergies.

Continue to STAT Plus to read the full story…

Read Original Article: STAT Plus: 7 things to know about Aimmune’s peanut allergy therapy ahead of a pivotal FDA meeting »